ARCUS BIOSCIENCES INC (RCUS)

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

RCUS Makes Bullish Cross Above Critical Moving Average

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/PRNewswire/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among...

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences Announces New Employment Inducement Grants

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

December 20th Options Now Available For Arcus Biosciences (RCUS)

Commit To Buy Arcus Biosciences At $15, Earn 30.4% Annualized Using Options

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

RCUS Crosses Above Key Moving Average Level

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Arcus Biosciences Announces New Employment Inducement Grants

Noteworthy Thursday Option Activity: RCUS, PG, MGM

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024

RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

RCUS Makes Bullish Cross Above Critical Moving Average

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia